How I diagnose and treat chronic myelomonocytic leukemia | Haematologica haematologica.org/article/view/h… #CMML

How I treat chronic myelomonocytic leukemia haematologica.org/article/view/h…

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma nature.com/articles/s4159…

Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents ashpublications.org/blood/article-…

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma mdpi.com/2033400 #mdpicancers via Cancers MDPI #mmsm

The crazy case of a #T-cell ALL that switched to acute myeloid leukemia shortly after #CART-cellTherapy targeting #CD7. #Myeloid switch could be a new escape mechanism of leukemia under the pressure of targeting CD7. haematologica.org/article/view/h…

Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma - Yamauchi - European Journal of Haematology - Wiley Online Library onlinelibrary.wiley.com/doi/full/10.11… #lymsm

How to write a journal article for publication: a beginner's guide: ⬇️ The hour-glass model⏳

Post #ASH24. Active myeloma drugs in one table with mechanism of action. Revised slide. Bookmark! Black font — Approved drugs Blue font — Investigational #ASH24VR

So that is how smart trial design help you to get impressive PFS results . You select pts with good biology at the end of induction chemo and then give them additional treatment that control arm good biology pts dont get and show that PFS becomes better . Excellent discussion

While a noble sentiment, Dara-KRD is neither FDA approved nor listed by NCCN as a category 1 (or even a preferred) regimen (due to a lack of Phase III data). The counterargument then is that you raise false expectations & put the patient at risk of financial toxicity.

#Myeloma Paper of the Day: Systematic review & meta-analysis of outcomes of hematopoietic stem cell transplant in primary plasma cell leukemia finds pooled 3 years OS, PFS/EFS & relapse rate (RR) in auto-HCT were 51%, 36 %, and 68%, respectively: pubmed.ncbi.nlm.nih.gov/39724831/. #mmsm

2024 FDA Novel Drug Approvals (with segmentation by manufacturer, indication and supporting clinical trials) The agency has approved 55 novel drugs so far, with 47 via CDER and 8 via CBER Other takeaways: • This is 22% behind 2023 which saw 71 approvals (16 CBER, 55 CDER) -

#Myeloma Paper of the Day: IMWG immunotherapy committee makes recommendations on sequencing immunotherapy for treatment of myeloma, including to avoid high-dose alkylators & bendamustine, give bridging if high disease burden, and CAR T before TCE: pubmed.ncbi.nlm.nih.gov/39870767/. #mmsm

Trained immunity in chronic inflammatory diseases and cancer bit.ly/4jCG2IK

February 2025 issue is available online. See and download for free the Haematologica Digital Edition! haematologica.org/preview/digita…

🥳 Our 7th most downloaded article in 2024: Cancer drug-tolerant persister cells: from biological questions to clinical opportunities by Alberto Bardelli, mariangela russo et. al bit.ly/3EDqQLd #persistercells #DTPs #resistance Cancer at Nature Portfolio #NRCtop10of2024

Congratulations to Anh Lam (she/her) for leading this work: “Innovations in Palliative Care Delivery in Oncology.” ascopubs.org/doi/10.1200/OP… ASCO JCO Oncology Practice Journal of Clinical Oncology #PallOnc #SuppOnc #PalliativeCare Laura Petrillo 🗽 Areej El-Jawahri

Mechanisms of antigenic escape to anti-GPRC5D TCEs in MM: i) biallelic deletion; ii) monoallelic deletion + single nucleotide variant; iii) epigenetic promoter silencing #mmsm #bmtsm Holly Lee nizar jacques bahlis nature.com/articles/s4159…

🔴Online now: Inter-rater reliability of CTCAE assessments with or without EORTC PRO data in a mixed cancer population: a multinational, open-label, RCT from EORTC Quality of Life Group (QLG) thelancet.com/journals/lanon… AND ✏️Linked Comment by Ethan Basch, Amylou Dueck, PhD thelancet.com/journals/lanon…